# Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

> **NCT03282851** · PHASE1 · COMPLETED · sponsor: **Fresenius Kabi SwissBioSim GmbH** · enrollment: 696 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MSB11456
- **DRUG:** US-licensed Actemra
- **DRUG:** EU-approved RoActemra

## Key facts

- **NCT ID:** NCT03282851
- **Lead sponsor:** Fresenius Kabi SwissBioSim GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 696 (ACTUAL)
- **Last updated:** 2020-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03282851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03282851, "Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03282851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*